China
Africa
Explore chapters and articles related to this topic
Unexplained Fever In Hematologic Disorders
Published in Benedict Isaac, Serge Kernbaum, Michael Burke, Unexplained Fever, 2019
Infections are a major cause of morbidity and mortality in patients with multiple myeloma (MM) and macroglobulinemia. Frequently bacterial infection is the presenting symptom of MM, ranging from 0.8 to 2.22 infections per patient per year.62 Though Streptococcus pneumoniae continues to be a significant problem, Gram-negative microorganisms presently account for over ⅔ of the infectious episodes.63 Sinopulmonary and urinary tract infections are the most common. Tumor mass, azotemia, and refractory disease have all been associated with an increased risk of infection.64 While the depression of normal marrow elements, in particular granulocytes, is an important feature of MM, a lack of correlation between infection and neutropenia has been noted.65 Patients with macroglobulinemia have less infectious episodes than those suffering from MM.66
Lymphocyte and plasma cell malignancies
Published in Gabriel Virella, Medical Immunology, 2019
Juan Carlos Varela, Gabriel Virella
Clinical presentation and diagnosis. Waldenström's macroglobulinemia is clinically characterized by a constellation of symptoms that include weakness and anemia, easy bruising, fever, headache, night sweats, weight loss, hyperviscosity-related symptoms (Table 27.1), hepatomegaly, splenomegaly, and lymphadenopathy. Neuropathy can also be present in these patients, apparently as a result of having an IgM monoclonal protein that binds to the myelin sheath and causes demyelination.
Noninfectious Pulmonary Manifestations of Renal Disease In Children
Published in Lourdes R. Laraya-Cuasay, Walter T. Hughes, Interstitial Lung Diseases in Children, 2019
Stephen T. Lawless, H. Jorge Baluarte
Macroglobulinemia has been associated with renal disease in myeloma, lymphoma, malignancy (including lymphoma), and immunodeficiency states. Renal tubular acidosis, nephropathy, and pulmonary infiltrates can occur.
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment
Published in OncoImmunology, 2022
Simone Kloch Bendtsen, Maria Perez-Penco, Mie Linder Hübbe, Evelina Martinenaite, Morten Orebo Holmström, Stine Emilie Weis-Banke, Nicolai Grønne Dahlager Jørgensen, Mia Aaboe Jørgensen, Shamaila Munir Ahmad, Kasper Mølgaard Jensen, Christina Friese, Mia Thorup Lundsager, Astrid Zedlitz Johansen, Marco Carretta, Niels Ødum, Özcan Met, Inge Marie Svane, Daniel Hargbøl Madsen, Mads Hald Andersen
Buffy coats from healthy, anonymized donors were acquired from the Blood Bank at Copenhagen University Hospital, Rigshospitalet, Denmark. According to the Danish Law of Research Ethics §14 section 3, the usage of anonymized biological material does not require approval from an ethics committee. Patient samples were collected at the National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital Herlev, in accordance with the provisions of the Declarations of Helsinki and informed, written consent. Patients had been diagnosed with malignant melanoma, multiple myeloma, breast-, kidney-or prostate cancer, myeloproliferative neoplasms or Waldenström’s macroglobulinemia. Peripheral blood mononuclear cells (PBMCs) were isolated and processed as described by Martinenaite et al.23 PBMCs were cultured in X–vivo 15 (Lonza, Basel, Switzerland) supplemented with 5% human serum.
Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response
Published in OncoImmunology, 2021
Dhon Roméo Makanga, Maxime Jullien, Gaëlle David, Nolwenn Legrand, Catherine Willem, Léa Dubreuil, Alexandre Walencik, Cyrille Touzeau, Thomas Gastinne, Benoit Tessoulin, Steven Le Gouill, Béatrice Mahé, Katia Gagne, Patrice Chevallier, Béatrice Clemenceau, Christelle Retière
From November 2019 to February 2020, 80 consecutive adult patients treated in our institution for an NHL with a rituximab-based immunochemotherapy were included after providing informed consent. Peripheral blood mononuclear cells (PBMCs) were isolated as previously described.11 Routine information, such as disease status, previous treatments received (including anterior exposure to rituximab), and CMV serology were collected from the medical file. The best response to immunochemotherapy at the end of the follow-up period (July 2020) was determined using Cheason 2007 revised criteria21 for patients with CT-measurable disease. Patients treated for a Waldenström macroglobulinemia with no CT-measurable disease were evaluated using Owen 2012 criteria.22 In both cases, complete response (CR) was defined as the disappearance of all evidence of disease, partial response (PR) as ≥ 50% regression of measurable disease, progressive disease (PD) as the appearance of any new lesion or ≥ 50% increase measurable disease, and stable disease (SD) as failure to attain CR/PR or PD. At the time of analysis, 6 patients did not have an assessment of disease response and were excluded.
Toxicities of novel therapies for hematologic malignancies
Published in Expert Review of Hematology, 2020
Florian Simon, Jorge Garcia Borrega, Paul J. Bröckelmann
BTK is an important part of the B-cell-receptor pathway and leads to activation of signaling pathways that ultimately promote tumor-cell survival [15,16]. Ibrutinib was the first BTKi approved for marketing by the FDA for the treatment of mantle cell lymphoma (MCL) and shortly thereafter for relapsed chronic lymphocytic leukemia (CLL) in 2013 and 2014, respectively. The approval was based on the results of two phase Ib/II trials which showed impressive response and PFS rates [15,17]. Due to further trials showing improved OS compared to conventional chemoimmunotherapy, BTKi has become one of the CLL first-line therapies [18]. Besides CLL and MCL, BTKis are administered in unfit Waldenström’s macroglobulinemia patients and in chronic graft versus host disease (cGvHD). Recently, second-generation BTKis such as acalabrutinib and zanubrutinib were granted approval by the FDA. Compared with classical chemo-(immuno-)therapy BTKi appears to have a favorable side effect profile both in phase III trials and routine care [19]. However, the distinct toxicities associated with BTKis require monitoring of patients for adverse events especially in the first months after initiation of therapy.